Industry Reports

Q1 2019
In our third quarterly edition of our Institutional Industry Report on the Bio/Pharma Outsourced Services (BPOS) sector, we focus on the BPOS industry’s opportunities to support the development and manufacture of cannabinoid-based drugs. We hasten, however, to dampen any prurient interest in this topic by emphasizing that these drugs have no “mind-altering” effects and will not be available through the marijuana dispensaries popping up like flowers in the spring.
Q1 2019
Policy changes towards patient-centered healthcare, including the transition from fee-for-service to value-based care and the 2019 transparency law requiring hospitals to list standard prices online, have encouraged a revamp of healthcare solutions and organizational needs. The trend towards consumerization has bolstered increased focus on Healthcare Information Technology (HCIT) solutions which are simplified, personalized, and interconnected for tracking and transparency.
Q1 2019
One of the hurdles consistently facing medical device original equipment manufacturers is the significant costs and length of time to design, develop, and secure regulatory clearance for a new product.
Q3 2018
Healthcare Information Technology companies have experienced robust demand as buyers seek inorganic growth opportunities to comply with regulatory requirements, adapt to changing reimbursement policies, and deliver cost-effective and efficient patient care.
Q4 2018
The cell and gene therapy community gathered recently in La Jolla at the annual “Meeting on the Mesa” of the Alliance for Regenerative Medicine to review the state of the industry. The mood was ebullient as attendees celebrated the emergence of the industry from “R&D/developmental puberty” into commercial adulthood. The clear consensus was that cell/gene therapy, benefiting from substantial R&D and development efforts over the last two decades, has come of age in its ability to provide trans-formative new treatments for patients.
Q4 2018
Within the Behavioral Healthcare Services industry, companies that offered child and youth-oriented services accounted for 24.3% or 17 of the announced or closed mergers and acquisitions year-to-date. Activity in this segment has largely been driven by the national rise in children with autism (a 15.0% increase from 2016 to 2018, according to Autism Speaks) and the ongoing battle against opioid abuse (which is most prevalent among young adults ages 18-to-25 years old).
Q4 2018
The Healthcare Staffing sector continues to benefit from an increasingly tight labor market due to strong economic conditions coupled with increased health care utilization as the US population agencies and a wave of retiring Baby Boomer healthcare practitioners. The gap between openings and hires in healthcare has been widening rapidly since 2014 reaching a projected labor gap in July of approximately 536,000 healthcare professionals according to the Bureau of Labor Statistics (BLS).
Q3 2018
We are pleased to present our Q3 2018 Medical Device Outsourcing Industry Markets, Mergers & Acquisitions Update.  By 2023, the Drug-Device Combination market value will reach $29.8 billion, increasing at a 13.8% compound annual growth rate from 2018 to 2023, a much faster growth than that of the overall Medical Device industry.  Drug-device combination products include any combination of a drug or biologic with a medical device.  Examples of drug-device combination products include prefilled drug delivery systems, drug-eluding stents, wearable injectors, and insulin deli
Q3 2018
Contract Research Organizations (CROs) remain the most targeted segment in the Pharmaceutical Outsourcing industry, accounting for 45.2% of deals to-date in 2018 compared to 38.3% in all of 2017. Buyers have sought to cut clinical trial times and reduce spending through these strategic acquisitions.  In August, Capstone Headwaters advised Gibraltar Laboratories on its sale to Sotera Health LLC, a portfolio company of Warburg Pincus and GTCR. 

Pages